Potentiation Of The Nasopharyngeal Carcinoma Cell Lines By Maritoclax To Abt-263 In 2-Dimensional And 3-Dimensional Cell Culture Methods by Lian, Benedict Shi Xiang
  
POTENTIATION OF THE NASOPHARYNGEAL 
CARCINOMA CELL LINES BY MARITOCLAX 
TO ABT-263 IN 2-DIMENSIONAL AND  
3-DIMENSIONAL CELL CULTURE METHODS 
 
 
 
 
 
 
 
BENEDICT LIAN SHI XIANG 
 
 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
2017 
  
POTENTIATION OF THE NASOPHARYNGEAL 
CARCINOMA CELL LINES BY MARITOCLAX 
TO ABT-263 IN 2-DIMENSIONAL AND  
3-DIMENSIONAL CELL CULTURE METHODS 
 
 
 
 
by 
 
 
 
BENEDICT LIAN SHI XIANG 
 
 
 
 
Thesis is submitted in fulfilment of the requirements  
for the degree of  
Master of Science 
 
 
 
 
 
May 2017
ii 
 
 
ACKNOWLEDGEMENT 
 
First and foremost, I would like to express my utmost gratitude to my project 
supervisor, Dr. Nethia Mohana-Kumaran for her unlimited support, encouragement, 
and patience throughout the studies. I would not have completed my studies without 
her endless guidance and tireless effort. Her unique way of supervision and impressive 
thinking had motivated me to work harder and at the same time unleash my hidden 
abilities.  
Next, I would like to express my deepest appreciation to my beloved parents, 
siblings and relatives for their understanding and motivation in my undertaking. I also 
wish to thank my dearest lab members in Lab 207, especially Kalaivani Muniandy, 
Crystal Phang and Prabu Siva Sankar for their guidance and assistance. Their 
knowledge and laboratory skills helped in solving my research questions and in 
completing my experiments. 
Last but not least, I would like to thank the staff, lab assistants and friends from 
the School of Biological Sciences, Institute for Research in Molecular Medicine 
(INFORMM), Malaysia Institute of Pharmaceuticals and Nutraceuticals (IPHARM) 
and Institute of Medical Research (IMR) for their cooperation and support during my 
visits and work.
iii 
 
TABLE OF CONTENTS 
 
Acknowledgement 
 
ii 
Table of Contents 
 
iii 
List of Tables 
 
viii 
List of Figures 
 
x 
List of Symbols and Abbreviations 
 
xii 
Abstrak 
 
xv 
Abstract  
 
xvii 
CHAPTER 1 INTRODUCTION 
 
1 
 1.1 Objectives 
 
3 
CHAPTER 2 LITERATURE REVIEW 
 
4 
 2.1 Nasopharyngeal Carcinoma – a distinct head and neck 
cancer 
 
4 
 2.2 Classification of Nasopharyngeal Carcinoma 
 
9 
 2.3 The Epstein-Barr virus (EBV) infection 
 
11 
 2.4 Treating Nasopharyngeal Carcinoma – where is the 
problem? 
 
12 
 2.5 Apoptosis Pathways 
 
18 
 2.6 The Extrinsic Apoptosis Pathway 
 
19 
 2.7 The Intrinsic Apoptosis Pathway 
 
20 
 2.8 The BCL-2 Family Proteins – critical regulators of the 
intrinsic apoptosis pathway 
 
21 
 2.9 Contribution of the BCL-2 family proteins to NPC 
progression 
 
24 
 2.10 Combination of ABT-263 with drugs which manipulate 
MCL-1 for NPC treatment 
 
26 
CHAPTER 3 MATERIALS AND METHODS 
 
29 
 3.1 Materials 29 
iv 
 
 3.1.1 Drugs 
 
29 
 3.1.2 Chemicals, Reagents and Consumables 
 
29 
  3.1.2(a) Cell Culture 
 
29 
  3.1.2(b) Two-dimentional (2D) cytotoxicity 
assay 
 
29 
  3.1.2(c) Three-dimentional (3D) spheroid 
work 
 
29 
  3.1.2(d) Protein extraction and quantification 
 
30 
  3.1.2(e) SDS-Page Gel Electrophoresis  
 
30 
  3.1.2(f) Antibodies 
 
30 
 3.1.3 Buffers and Solutions 
 
31 
 3.1.4 Equipment 
 
32 
 3.1.5 Software 
 
32 
3.2 Methods 
 
33 
 3.2.1 Cell Culture 
 
33 
 3.2.2 Trypsinisation of cells 
 
34 
 3.2.3 Cryopreservation 
 
34 
 3.2.4 Cell Counting 
 
35 
 3.2.5 Two-dimentional (2D) Cytotoxicity Assay 
 
36 
  3.2.5(a) Drug combination studies 
 
37 
  3.2.5(b) Test of synergy 
 
37 
 3.2.6 Three-dimentional (3D) NPC spheroids 
 
38 
  3.2.6(a) Generating 3-dimentional (3D) NPC 
spheroids 
 
38 
  3.2.6(b) Embedding NPC spheroids into 
collagen matrix 
39 
  3.2.6(c) Live-dead staining of spheroids 
 
40 
v 
 
 3.2.7 Sodium dodecyl sulphate-polyacrylamide 
(SDS-PAGE) gel electrophoresis  
 
41 
  3.2.7(a) Preparation of protein lysates 
 
41 
  3.2.7(b) Protein Quantification 
 
41 
  3.2.7(c) Gel electrophoresis 
 
42 
  3.2.7(d) Wet electroblotting 
 
43 
  3.2.7(e) Antibody probing and imaging 
 
44 
 3.2.8 SDS-PAGE gel electrophoresis (Dose- and 
Time-dependent assay  
 
46 
CHAPTER 4 RESULTS: INVESTIGATING THE 
SENSITIVITY OF NPC CELL LINES HK-1 AND 
C666-1 TO COMBINATION OF ABT-263 AND 
MARITOCLAX IN 2-DIMENTIONAL (2D) CELL 
CULTURE MODEL 
 
47 
4.1 NPC cell lines are resistant to single agent activity of 
ABT-263 
 
47 
4.2 Basal levels of the anti-apoptotic proteins in the NPC 
cell lines  
 
49 
4.3 Maritoclax reduces the level of MCL-1 in the HK-1 and 
C666-1 cells in a dose- and time-dependent manner 
 
50 
4.4 Synergistic anti-proliferative effects of ABT-263 and 
Maritoclax in the HK-1 cells 
 
52 
4.5 Potentiation of the HK-1 cells to ABT-263 by 
Maritoclax 
 
54 
4.6 Potentiation of the HK-1 cells to Maritoclax by ABT-
263 
 
58 
4.7 Synergistic anti-proliferative effects of ABT-263 and 
Maritoclax in the C666-1 cells 
 
60 
4.8 Potentiation of the C666-1 cells to ABT-263 by 
Maritoclax 
 
62 
4.9 Potentiation of the C666-1 cells to Maritoclax by ABT-
263 
66 
vi 
 
CHAPTER 5 RESULTS: INVESTIGATING THE 
SENSITIVITY OF THE NPC CELLS TO 
COMBINATION OF ABT-263 AND 
MARITOCLAX IN A 3-DIMENTIONAL (3D) 
SPHEROID MODEL 
 
69 
5.1 Generation of 3D spheroids from NPC cell lines HK-1 
and C666-1 
 
69 
5.2 Maritoclax potentiates 3D HK-1 spheroids to ABT-263 
 
72 
5.3 Combination of ABT-263 and Maritoclax increased cell 
death in the C666-1 loose aggregates 
 
77 
CHAPTER 6 RESULTS: INVESTIGATING THE 
SENSITIVITY OF THE NPC CELL LINES TO 
COMBINATION OF ABT-263 AND 
SIMVASTATIN 
 
80 
6.1 Synergistic anti-proliferative effects of ABT-263 and 
Simvastatin in the HK-1 cells 
 
80 
6.2 Potentiation of the HK-1 cells to ABT-263 by 
Simvastatin 
 
82 
6.3 Potentiation of the HK-1 cells to Simvastatin by ABT-
263 
 
84 
6.4 Synergistic anti-proliferative effects of ABT-263 and 
Simvastatin in the C666-1 cells 
 
86 
6.5 Potentiation of the C666-1 cells to ABT-263 by 
Simvastatin 
 
88 
6.6 Potentiation of the C666-1 cells to Simvastatin by ABT-
263 
 
90 
CHAPTER 7 DISCUSSION 
 
93 
7.1 Maritoclax sensitises NPC cell lines HK-1 and C666-1 
to ABT-263 in 2D cell culture model 
 
93 
7.2 Testing the combination of ABT-263 and Maritoclax in 
3D NPC spheroids 
98 
 7.2.1 Formation of 3D spheroids from the NPC cell 
lines HK-1 and C666-1 
 
98 
 7.2.2 Combinatorial treatment of 3-dimensional (3D) 
NPC spheroids with ABT-263 and Maritoclax 
 
101 
vii 
 
CHAPTER 8 CONCLUSION AND FUTURE WORK 
 
104 
  REFERENCES 
 
109 
  APPENDICES 
 
 
viii 
 
LIST OF TABLES 
 
 Page 
 
Table 2.1 Countries with the highest incidence rates of 
Nasopharyngeal carcinoma in Southeast Asia 
 
6 
Table 2.2 Chronology of WHO classification of NPC 
 
10 
Table 3.1 Description of Combination Index (CI) for drug 
combination analyses 
 
38 
Table 3.2 The concentrations of primary and secondary antibodies, 
incubation times and washing times employed in this study 
 
45 
Table 4.1 The mean CI values and description of drug combination 
interactions in the HK-1 cells 
 
53 
Table 4.2 
 
 
Table 4.3 
Potentiation of the HK-1 cells to ABT-263 by Maritoclax 
(fold sensitisation) 
 
The mean CI values and the description of the drug 
combination interactions of potentiation of the HK-1 cells 
to ABT-263 by Maritoclax 
 
56 
 
 
56 
Table 4.4 Potentiation of the HK-1 cells to Maritoclax by ABT-263 
(fold sensitisation) 
 
60 
Table 4.5 The mean CI values and the description of the drug 
combination interactions in the C666-1 cells  
 
62 
Table 4.6 
 
 
Table 4.7 
Potentiation of the C666-1 cells to ABT-263 by Maritoclax 
(fold sensitisation) 
 
The mean CI values and the description of the drug 
combination interactions of potentiation of the C666-1 cells 
to ABT-263 by Maritoclax 
 
64 
 
 
64 
Table 4.8 Potentiation of the C666-1 cells to Maritoclax by ABT-263 
(fold sensitisation) 
 
67 
Table 6.1 The mean CI values and the description of the drug 
combination interactions in the HK-1 cells 
 
82 
Table 6.2 Potentiation of the HK-1 cells to ABT-263 by Simvastatin 
(fold sensitisation) 
 
84 
Table 6.3 Potentiation of the HK-1 cells to Simvastatin by ABT-263 
(fold sensitisation) 
 
86 
ix 
 
Table 6.4 The mean CI values and the description of the drug 
combination interactions in the C666-1 cells 
 
88 
Table 6.5 Potentiation of the C666-1 cells to ABT-263 by Simvastatin 
(fold sensitisation) 
 
90 
Table 6.6 Potentiation of the C666-1 cells to Simvastatin by ABT-263 
(fold sensitisation) 
92 
x 
 
LIST OF FIGURES 
 
 Page 
  
Figure 2.1 Anatomy of the human pharynx 
 
4 
Figure 2.2 The ten most frequent cancers in Malaysia 
 
7 
Figure 2.3 The ten most common cancer affecting males in Malaysia 
 
7 
Figure 2.4 Incidence rates of NPC in males in selected states in 
Malaysia. 
 
8 
Figure 2.5 The Apoptosis Pathways 
 
18 
Figure 2.6 The BCL-2 homology (BH) domains of the BCL-2 family 
members 
 
21 
Figure 2.7 BH3-only pro-apoptotic proteins specifically bind and 
inhibit the anti-apoptotic proteins 
 
23 
Figure 2.8 Combining ABT-263 with Maritoclax/Simvastatin to 
induce apoptosis in the NPC cell lines HK-1 and C666-1 
(experimental plan and expected outcome) 
 
28 
Figure 3.1 The 96-well plate layout for the 2D cytotoxicity assay 
 
37 
Figure 3.2 The 24-well plate layout for the 3D spheroid assay 
 
40 
Figure 3.3 Assembly of the transfer sandwich 
 
43 
Figure 4.1 HK-1 cells resistant to single agent treatment of ABT-263 
 
48 
Figure 4.2 C666-1 cells resistant to single agent treatment of ABT-263 
 
48 
Figure 4.3 Basal levels of the anti-apoptotic proteins in the NPC cell 
lines 
 
49 
Figure 4.4 Maritoclax reduced the level of MCL-1 in a dose- and time-
dependent manner 
 
51 
Figure 4.5 Synergistic anti-proliferative effects of ABT-263 and 
Maritoclax in the HK-1 cells at 1:1 drug concentration 
ratios 
 
52 
Figure 4.6 Test of synergy between ABT-263 and Maritoclax in the 
HK-1 cells  
 
53 
Figure 4.7 Potentiation of the HK-1 cells to ABT-263 by Maritoclax 
 
55 
xi 
 
Figure 4.8 Potentiation of the HK-1 cells to Maritoclax by ABT-263 59 
Figure 4.9 Synergistic anti-proliferative effects of ABT-263 and 
Maritoclax in the C666-1 cells at 1:1 drug concentration 
ratios  
 
61 
Figure 4.10 Test of synergy between ABT-263 and Maritoclax in the 
C666-1 cells 
 
61 
Figure 4.11 Potentiation of the C666-1 cells to ABT-263 by Maritoclax 
 
63 
Figure 4.12 Potentiation of the C666-1 cells to Maritoclax by ABT-263 
 
67 
Figure 5.1 Formation of HK-1 and C666-1 3D spheroids 
 
71 
Figure 5.2 Potentiation of the 3D HK-1 spheroids to ABT-263 by 
Maritoclax and vice versa 
 
73 
Figure 5.3 Effect of combination of ABT-263 and Maritoclax on 
C666-1 loose aggregates over 3 days 
 
78 
Figure 6.1 Synergistic anti-proliferative effects of ABT-263 and 
Simvastatin in the HK-1 cells at 1:1 drug concentration 
ratios  
 
81 
Figure 6.2 Test of synergy between ABT-263 and Simvastatin in the 
HK-1 cells 
 
81 
Figure 6.3 Potentiation of the HK-1 cells to ABT-263 by Simvastatin 
 
83 
Figure 6.4 Potentiation of the HK-1 cells to Simvastatin by ABT-263 
 
85 
Figure 6.5 Synergistic anti-proliferative effects of ABT-263 and 
Simvastatin in the C666-1 cells at 1:1 drug concentration 
ratios 
 
87 
Figure 6.6 Test of synergy between ABT-263 and Simvastatin in the 
C666-1 cells 
 
87 
Figure 6.7 Potentiation of the C666-1 cells to ABT-263 by Simvastatin 
 
89 
Figure 6.8 Potentiation of the C666-1 cells to Simvastatin by ABT-263 
 
91 
Figure 7.1 Maritoclax and ABT-263 synergistically induce apoptosis 
in NPC cells HK-1 and C666-1 through reduction of MCL-
1level 
 
103 
Figure 8.1 Combination of Maritoclax and ABT-263 synergistically 
induced apoptosis in the NPC cells lines HK-1 and C666-1 
 
105 
xii 
 
LIST OF SYMBOLS AND ABBREVIATIONS 
 
2D 2-dimensional 
3D 3-dimensional 
Akt Protein kinase B 
APAF-1 Apoptotic protease activating factor 1 
ApoG2 Apogossypolone  
BAD BCL-2 antagonist of cell death 
BART BamHI-A region rightward transcript 
BAK BCL-2 antagonist killer 1 
BAX BCL-2 associated X protein 
BCL-2 B-cell lymphoma-2 
BCL-XL B-cell lymphoma-extra large 
BCL-w B-cell lymphoma-2 like protein 
BCL-2 ASO Bcl-2 oligodeoxynucleotide antisense  
BFL-1/A1 B-cell related protein A1 
BH BCL-2 homology 
BID BCL-2 interacting domain death agonist 
BIK BCL-2 interacting killer 
BIM BCL-2 interacting mediator of cell death 
BMF BCL-2 modifying factor 
BOK BCL-2 related ovarian killer 
CTAR C-terminal activating region 
DF Death factor 
DR Death receptor 
xiii 
 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
EBV Epstein-Barr virus 
EBER EBV-encoded small RNA 
EBNA EBV-determined nuclear antigen 
EDTA Ethylenediaminetetraacetic acid 
EGFR Epidermal growth factor receptor 
EMEM Eagle's Minimum Essential Medium 
FADD Fas-associated death domain 
FASL Fas ligand 
FBS Fetal bovine serum 
FJX1 Four-jointed box 1 
HMG-CoA 3-hydroxy-3-methylglutaryl coenzyme-A 
HRK Harakiri 
IHC Immunohistochemistry  
IMRT Intensity-modulated radiotherapy 
JAK Janus kinase 
JNK Jun N-terminal kinase 
LMP Latent membrane protein 
MAPK Mitogen-activated protein kinases 
MCL-1 Myeloid cell leukaemia 1 
MOMP Mitochondrial outer membrane permeabilization 
mTOR Mammalian target for Rapamycin 
NaHCO₃ Sodium bicarbonate 
NF-κ B Nuclear factor κ -B 
xiv 
 
NPC Nasopharyngeal carcinoma 
NOXA Phorbol-12-myristate-13-acetate-induced protein-1 (NOXA) 
OMM Outer mitochondrial membrane 
PI3K Phosphoinositol-3-kinase 
PUMA p53-upregulated modulator of apoptosis 
RPMI Rosewell Park Memorial Institute 1640 
SDS Sodium dodecyl sulphate 
STAT Signal transducers and activators of transcription  
tBID Truncated BID 
TM Transmembrane 
TNF Tumour necrosis factor 
TRAIL TNF related apoptosis-inducing ligand 
ULA Ultralow-attachment 
VEGF Vascular endothelial growth factor 
VDAC Voltage-dependent anion channel 
WHO World Health Organization 
xv 
 
POTENSIASI SEL KANSER NASOFARINKS OLEH MARITOCLAX 
KEPADA ABT-263 DALAM KAEDAH SEL KULTUR  
2-DIMENSI DAN 3-DIMENSI 
 
ABSTRAK 
Malaysia mempunyai kes kanser nasofarinks, lebih dikenali sebagai kanser 
pangkal hidung, yang tertinggi di dunia. Kanser nasofarinks merupakan sejenis kanser 
yang boleh diubati jika dirawat pada peringkat awal. Namun demikian, rawatan yang 
sedia ada amat terhad untuk merawat kanser nasofarinks yang berulangan atau barah 
yang dikesan pada pringkat lewat. Matlamat kajian ini adalah untuk mensasar protein 
famili BCL-2 yang memainkan peranan penting dalam apoptosis. Beberapa protein 
dalam famili ini terutamanya protein anti-apoptotik diekspres pada tahap yang tinggi 
dalam tisu NPC dan oleh itu menjadi sasaran utama terapeutik. Kepentingan klinikal 
dalam mensasar protein ini meningkat dengan kejayaan pembangunan mimetik BH3, 
yang mensasar protein anti-apoptotik secara spesifik. Perencat molekul kecil BH3 
yang dikenali sebagai ABT-263 boleh merencatkan protein anti-apoptotik BCL-2, 
BCL-XL dan BCL-w, telah menunjukkan hasil rawatan yang memberansangkan 
dalam kanser hematopoitik dan kanser paru-paru sel kecil tetapi tidak berkesan dalam 
tumor pepejal, termasuk kanser nasofarinks. Hal ini disebabkan oleh pengekspresan 
protein MCL-1 dalam tumor pepejal yang menyebabkan sel kanser resistan terhadap 
rawatan ABT-263. Justeru itu, pengawalan ekspresi protein MCL-1 dalam tumor 
pepejal dengan menggunakan drug yang dapat menurunkan tahap MCL-1 atau 
meneutralkan MCL-1 dijangka mampu meningkatkan kesensitifan sel kanser kepada 
ABT-263. Di sini saya melaporkan bahawa pengurangan tahap MCL-1 dalam kedua-
dua titisan sel kanser nasofarinks, iaitu HK-1 dan C666-1 oleh Maritoclax, bergantung 
xvi 
 
kepada konsentrasi drug dan tempoh rawatan. Hasil daripada gabungan antara 
Maritoclax dan ABT-263 ke atas dua jenis titisan sel kanser nasofarinks telah 
menunjukkan kesan sinergistik. Kajian potensi drug juga menunjukkan kedua-dua 
titisan sel HK-1 dan C666-1 dapat disensitifkan oleh Maritoclax kepada ABT-263 
tetapi potensi drug pada arah yang bertentangan didapati lemah. Hasil kajian yang 
sama turut dijalankan dengan menggunakan kaedah kultur sel 3D. Kaedah kultur sel 
3D telah digunakkan kerana ia menyifatkan persekitaran mikro dan arkitektur tumor 
in vivo. Maritoclax dapat meningkatkan kesensitifan sferoid 3D HK-1 kepada ABT-
263 tetapi kesensitifan sferoid kepada Maritoclax oleh ABT-263 didapati lemah. 
Gabungan dengan Maritoclax juga mensensitifkan gugusan longgar C666-1 kepada 
ABT-263. Lebih penting, kedua-dua HK-1 dan C666-1 tidak menunjukkan resistan 
terhadap kombinasi Maritoclax dan ABT-263. Hasil kajian awal mendapati bahawa 
Simvastatin dapat mensensitifkan HK-1 dan C666-1 kepada ABT-263. Walaupun 
ABT-263 tidak dapat meningkatkan kesensitifan sel HK-1 kepada Maritoclax, ia agak 
berkesan dalam mensensitikan sel C666-1 kepada Maritoclax tetapi dalam tetingkap 
yang sempit. Secara keseluruhan, kajian menunjukkan bahawa kombinasi drug yang 
dikaji, mempunyai potensi sebagai strategi rawatan kanser nasofarinks. Kajian yang 
lebih lanjut dengan menggunakan sferoid 3D dan model preklinikal diperlukan untuk 
membongkar sepenuhnya prospek kombinasi ini.
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POTENTIATION OF THE NASOPHARYNGEAL CARCINOMA CELL 
LINES BY MARITOCLAX TO ABT-263 IN 2-DIMENSIONAL AND 3-
DIMENSIONAL CELL CULTURE METHODS 
 
ABSTRACT 
Malaysia has one of the highest incidences of Nasopharyngeal carcinoma 
(NPC) in the world.  The cancer is remarkably curable at early stages but treatment 
options become limited when patients develop a recurrence or diagnosed late, leaving 
them with very little hope to combat the cancer. The goal of this project is to 
pharmacologically target the BCL-2 family proteins, the critical regulators of the 
apoptosis pathway. Some members of the anti-apoptotic proteins are highly expressed 
in NPC tissues and hence have become attractive therapeutic targets. Clinical interest 
in targeting these proteins increased with the successful development of BH3-
mimetics, which selectively target the anti-apoptotic proteins. BH3-mimetic ABT-263, 
which selectively inhibits BCL-2, BCL-XL and BCL-w, showed impressive single 
agent activity in hematopoietic tumours and small cell lung carcinoma (SCLC) but the 
effect of this drug as monotherapy was disappointing in most solid tumours, including 
NPC. Anti-apoptotic protein MCL-1 was characterised as the resistance factor of ABT-
263 in solid tumours and hence, chemotherapeutic agents or targeted therapies that can 
reduce the level or neutralise MCL-1 are predicted to synergise with ABT-263. Here I 
report that Maritoclax reduced the level of MCL-1 in a dose- and time-dependant 
manner. Combination of Maritoclax and ABT-263 exhibited synergistic effects on the 
NPC cell lines HK1 and C666-1. Drug potentiation studies revealed that Maritoclax 
sensitised both HK1 and C666-1 cells to ABT-263 but potentiation was weaker in the 
opposite direction. Similar results were obtained when the combination was tested in 
xviii 
 
the 3D cell culture model. The 3D cell culture model was employed as it recapitulates 
tumour microenvironment and architecture more closely to tumour in vivo. Maritoclax 
potentiated the 3D HK-1 spheroids to ABT-263 but potentiation of the HK-1 spheroids 
to Maritoxlax by ABT-263 was weak. Combination with Maritoclax markedly 
sensitised the C666-1 loose aggregates to ABT-263. More notably, both HK-1 and 
C666-1 cells did not develop resistance to the combination rapidly. Preliminary data 
demonstrated that Simvastatin sensitised the HK-1 and the C666-1 cells to ABT-263 
but potentiation in the reverse direction was modest in the HK-1 cells. Surprisingly, 
ABT-263 sensitised the C666-1 cells to Simvastatin but this sensitisation occurred in 
a narrow window. Collectively, the findings illustrate that the combinations 
investigated could be potential treatment strategies for NPC but further studies in 3D 
and preclinical models are warranted to fully unravel the prospects of the duos. 
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CHAPTER 1 
 
INTRODUCTION 
 
Nasopharyngeal carcinoma (NPC) is an aggressive and deadly cancer. NPC is 
the sixth most common cancer in Southeast Asia with Malaysia reporting one of the 
highest national incidences (Jemal et al., 2011). NPC is curable with radical 
radiotherapy when detected early but the high probability of distant metastases reduces 
patient survival (Wee et al., 2010; Zhang et al., 2013). The median survival time for 
patients who are suffering from advanced NPC is only 5-11 months (Lee et al., 2012a; 
Zhang et al., 2013). Treating patients with a recurrence or advanced NPC is often a 
challenge as these patients rapidly develop resistance to chemo- and radiotherapy. 
Thus, novel and improved treatment strategies are urgently needed to curb this disease. 
Cancer cells evade apoptosis through various strategies and one such strategy 
is to up-regulate the anti-apoptotic proteins (e.g. BCL-2, BCL-XL) (Hanahan and 
Weinberg, 2011). Increase in the level of these proteins in cancer has made them ideal 
targets for therapy and interest to target these proteins mounted with the generation of 
BH3-mimetics such as the first generation ABT-737 and now ABT-263 (Navitoclax). 
ABT-737/263 mimic pro-apoptotic protein BAD and specifically inhibits anti-
apoptotic proteins BCL-2, BCL-XL and BCL-w (Oltersdorf et al., 2005; Tse et al., 
2008). The mimetics exhibited encouraging outcome in haematological tumours and 
small cell lung cancer (SCLC) and now in various phases of clinical trials (Delbridge 
et al., 2016). The impressive outcome observed in haematological tumours and small 
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cell lung cancer (SCLC) was not mimicked in the solid tumours. Anti-apoptotic protein 
MCL-1 was reported to confer resistance to ABT-737/263 in solid tumours (van Delft 
et al., 2006; Tse et al., 2008) and hence combining ABT-263 with drugs which either 
neutralise MCL-1 or induce MCL-1 antagonist NOXA have been shown to reverse the 
acquired resistance and sensitise cells to ABT-737/263. 
 Preliminary data in the laboratory revealed that NPC cell lines HK-1 and  
C666-1 were resistant to single agent treatment of ABT-263 except at unrealistically 
high-concentrations. The purpose of this study is to sensitise the NPC cell lines to 
ABT-263 by combining ABT-263 with Maritoclax or Simvastatin. Maritoclax was 
reported to inhibit MCL-1 in leukaemia cells (Doi et al., 2012; Doi et al., 2014) and 
on the other hand Simvastatin was reported to induce BH3-only proteins NOXA and 
PUMA, which neutralise MCL-1 (Ghavami et al., 2010). The NPC cells C666-1 and 
HK-1 were tested for sensitivity to ABT-263 and Maritoclax or Simvastatin first as 
single agents and later as combinations at various concentrations using 2-dimensional 
(2D) drug sensitivity assay. Drug potentiation or drug sensitisation studies were carried 
out to determine if uptake of one drug will enhance the sensitivity of the cells to 
another drug. Drug potentiation effects are distinct possibilities that must be 
considered to fully unravel the potential of the drug combinations. The 2D assays were 
followed by testing the sensitivity of the combinations in 3-dimentional (3D) NPC 
spheroids as 3D model epitomises tumour microenvironment and architecture more 
closely to tumours in vivo (Beaumont et al., 2013). 
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1.1 Objectives 
 
Objective 1: To investigate the sensitivity of the NPC cell lines HK-1 and C666-1 to 
combination with Maritoclax or Simvastatin with BH3 mimetic ABT-263 in activating 
the intrinsic apoptosis pathway. 
 
Objective 2: To investigate the potentiation of the NPC cell lines to ABT-263 by 
Maritoclax or Simvastatin and vice versa. 
 
Objective 3: To establish 3D spheroids from NPC cell lines HK-1 and C666-1 and test 
the sensitivity of the spheroids to combination of Maritoclax and ABT-263.
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 Nasopharyngeal Carcinoma – a distinct head and neck cancer  
Nasopharyngeal carcinoma (NPC) affects the nasopharynx, which is situated 
on the upper region of the pharynx (Probst et al., 2005) (Figure 2.1). More precisely, 
NPC manifests beneath the nasopharyngeal mucosa or within the pharyngeal recess, 
which is also known as the Fossa of Rosenmüller (Hoe, 1989; Sham et al., 1990).  
 
Figure source: www.cancer.gov 
Figure 2.1: Anatomy of the human pharynx. The pharynx is divided into three 
regions. Nasopharynx is situated on the uppermost part of the pharynx, followed by 
the oropharynx and hypopharynx. 
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NPC has remarkable distinct regional and racial prevalence. The cancer is less 
prevalent among the Caucasians but is rampant among the southern Chinese, Inuits of 
Alaska and native Greenlanders (Nielsen et al., 1977; Parkin et al., 1992). In Southern 
China, high NPC incidence rates were recorded particularly in the province of 
Guangdong, Guangxi, Hainan, Jiangxi, Hunan and Fujian (Zhang et al., 2007). 
Cantonese inhabiting these regions were reported to have the highest rate of NPC 
incidence (Zhang et al., 2007). Interestingly, incidence rate of NPC in Northern China 
is low (Wei et al., 2014). 
The incidence of NPC continues to be high among Chinese emigrants to Alaska, 
Greenland, Canada and North America but the incidences are low among ethnic 
Chinese who are born in North America (Buell, 1974; Torre et al., 2015). High 
incidences of NPC have also been reported in Hong Kong, Taiwan, Philippines, 
Thailand, India and Africa (Hsu et al., 2006; Torre et al., 2015). The distinct 
geographic and ethnic distribution of NPC demonstrate the multifactorial etiology of 
the cancer, including environmental factors which may include exposure to 
nitrosamines and consumption of salted and pickled food (Zou et al., 1994), genetic 
susceptibility and Epstein-Barr virus (EBV) infection (Yu et al., 1981; Brennan, 2006; 
Li et al., 2007). 
Incidence and mortality rates of NPC in Southeast Asia was the highest (Torre 
et al., 2015) compared to other countries with high NPC incidence and mortality rates 
(Torre et al., 2015).  Among the Southeast Asian countries, high incidence of NPC 
was recorded in countries namely Malaysia, Indonesia and Singapore (Table 2.1). The 
incidence and mortality rates of NPC were two to three times higher in males compared 
to females (Jemal et al., 2011) (Table 2.1).  
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Table 2.1: Countries with the highest incidence rates of Nasopharyngeal 
carcinoma in Southeast Asia. 
Nations Incidence rate 
(Age-standardized rate per 
100,000) 
Mortality rate 
(Age-standardized rate per 
100,000) 
Male Female Male Female 
Malaysia 10.6 3.9 3.9 1.2 
Singapore 9.7 3.2 4.4 1.3 
Indonesia 8.3 3.0 5.0 1.6 
Vietnam 7.7 3.4 4.8 2.0 
Brunei 7.6 1.5 3.4 0.5 
 
Adapted from: Jemal et al., 2011 
NPC was ranked as the fourth most common cancer in Malaysia and the third 
most common cancer affecting Malaysian males (Omar and Tamin, 2011) (Figures 2.2 
and 2.3). The incidences were higher in males residing in Johor, Sabah and Sarawak 
(Figure 2.4). The ethnic Chinese recorded the highest NPC incidence compared to the 
Malays and the Indians in Peninsular Malaysia whereas the Bidayuh population 
recorded the highest NPC incidences in Sarawak compared to the Chinese and the 
Malays (Devi et al., 2004). Interestingly, the incidences of NPC among ethnic Indians 
are low (Devi et al., 2004). 
In Singapore, NPC is the eighth most common cancer. Similar to Malaysia, 
NPC is common among Chinese compared to the other races in Singapore (Lee et al., 
2014). Whilst in Indonesia, NPC is the fourth most common cancer after cervical and 
breast cancers and melanoma. NPC was more common in some local natives of 
Indonesia compared to the others. The cancer was more widespread among the 
Javanese followed by the Sundanase and the Sumatranese natives (Adham et al., 2012).  
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Figure source: National Cancer Registry Report 
2007, Ministry of Health, Malaysia 
 
Figure 2.2: The ten most frequent cancers in Malaysia. NPC (red box) is ranked 
number four after breast, colorectal and trachea, bronchus and lung carcinoma.  
 
 
Figure source: National Cancer Registry Report 
2007, Ministry of Health, Malaysia 
 
Figure 2.3: The ten most common cancers affecting males in Malaysia. NPC (red 
box) is ranked third after trachea, bronchus and lung carcinoma and colorectal 
carcinoma.  
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Adapted from: National Cancer Registry Report 
2007, Ministry of Health, Malaysia 
 
Figure 2.4: Incidence rates of NPC in males in selected states in Malaysia. Note: 
No data was reported for Kelantan, Kedah, Terengganu and Malacca as NPC was not 
the top five most common malignancies in these states.  
 
Reports from diverse sources demonstrate that incidences of NPC are the 
highest in Southeast Asia, particularly in Malaysia. NPC is highly sensitive to radical 
radiotherapy if diagnosed early but due to its trivial clinical symptoms, NPC is usually 
detected at late stages (stage III and IV) (Pua et al., 2008). Patients who are diagnosed 
at late stages and patients who are suffering from a recurrence do not respond well to 
radio- and chemotherapy. Sadly, due to limited second line treatments, patients often 
do not survive the cancer. Hence, novel and improved treatment strategies are 
necessary to improve patient survival. This will be further elaborated in section 2.4. 
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2.2 Classification of Nasopharyngeal Carcinoma 
The World Health Organization (WHO), in 1978, classified NPC into three 
histological subtypes: keratinizing squamous cell carcinoma (WHO type 1) – 
distinguished by well differentiated cells which produce keratin, nonkeratinizing 
carcinoma (WHO type 2) – contains cells which varies in cell differentiation but lack 
keratin and undifferentiated carcinoma (WHO type 3) (Table 2.2) – distinguished by 
poorly differentiated cells which exists in many different types of cells namely clear 
cell, spindle cell and anaplastic cell (Shanmugaratnam and Sobin, 1978) . The WHO 
classification was amended in 1991. In this amendment, the keratinizing squamous 
cell carcinoma was retained while WHO types 2 and 3 were merged under one 
category known as “nonkeratinizing squamous cell carcinoma”. This category was 
further subdivided into differentiated and undifferentiated nonkeratinizing carcinoma 
(Shanmugaratnam, 1991) (Table 2.2). The amended classification eliminated the use 
of numerical designation of WHO types 1, 2 and 3. The present WHO classification 
of NPC still follows the 1991 classification with addition of another category: basaloid 
squamous cell carcinoma (Barnes, 2005) (Table 2.2). Although NPC classification is 
amended, most research papers and books do not embrace the amended classification 
but rather continue using the WHO numerical system to report on the histologic 
subtypes of NPC. 
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Table 2.2: Chronology of WHO classification of NPC 
WHO Classification of NPC 
1978 1991 Present 
Type 1 - Keratinizing 
squamous-cell carcinoma 
 
Keratinizing squamous-cell 
carcinoma 
Keratinizing squamous-cell 
carcinoma  
Type 2 - Nonkeratinizing 
squamous-cell carcinoma 
Nonkeratinizing squamous-
cell carcinoma 
 
Differentiated  
 
Undifferentiated  
 
Nonkeratinizing squamous-
cell carcinoma 
 
Differentiated 
 
Undifferentiated  
 
Type 3 - Undifferentiated 
carcinoma 
 
Basaloid squamous-cell 
carcinoma 
Adapted from: Barnes, 2005 
 
Interestingly, the histologic subtypes of NPC vary with different geographical 
areas. NPC type III is common in both low NPC-incidence and high NPC-incidence 
areas. North America, which represents a low-incidence area and Southern China, 
which represents a high-incidence area comprise of 65% and >95% of NPC type III 
respectively. Meanwhile, incidences of NPC types I and II are higher in low-
prevalence areas such as Northern America with 25% and 12% respectively. On the 
other hand, in Southern China, the occurrence of NPC types I and II is less than 5% 
(Tao and Chan, 2007).  
NPC types II and III are strongly associated with Epstein-Barr virus (EBV) 
infection whereas EBV infection is normally absent in NPC type I (Marks et al., 1998). 
However, another study reported that all NPCs regardless of their histologic subtype 
contain EBV infection (Vasef et al., 1997). In Malaysia, a multi-centre NPC study 
conducted by the Malaysian Nasopharyngeal Carcinoma Study Group reported that 
97% of new NPC cases were either histologic subtype II or III. Only six patients 
suffered from WHO NPC type I (Pua et al., 2008).  
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2.3 The Epstein-Barr virus (EBV) infection 
Tony Epstein and Yvonne Barr first described Epstein-Barr virus in 1964. EBV 
is a human gamma-herpes virus which has a double-stranded DNA in an enclosed 
envelope (Baer et al., 1984). It has a large genome which is approximately 180kb and 
consists of about 80 open reading frames (Baer et al., 1984). Although EBV infects 
over 95% of humans worldwide, it remains harmless until the equilibrium between the 
host and the virus is tipped (Cohen, 2000). EBV is associated with a number of 
malignant carcinomas namely Hodgkin’s lymphoma, Burkitt’s lymphoma, oral hairy 
leukoplakia, gastric carcinoma and NPC (Young and Rickinson, 2004). EBV infection 
is normally not detected in normal epithelium of individuals at high risk of developing 
NPC and low-grade pre-invasive lesions but deletion of regions of chromosome 3p 
and 9p are detected in these individuals indicating that genetic events occur early in 
NPC pathogenesis. These early genetic events are believed to lead to subsequent EBV 
infection (Lo and Huang, 2002). EBV infection renders cells with growth and survival 
benefits leading to NPC manifestation (see paragraph below). Additional genetic and 
epigenetic alterations for example inactivation of the tumour suppressor genes 
CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A), RASSF1A (Ras association 
domain family 1 isoform A) and induction of anti-apoptotic gene BCL-2 lead to high-
grade pre-invasive lesions before the cancer metastasizes to distant organs (Barnes, 
2005; Young and Rickinson, 2004). 
The transforming capabilities of EBV is rendered by a set of latent genes 
known as the latent membrane proteins (LMP-1, LMP-2A and LMP-2B), EBV-
determined nuclear antigens (EBNA) namely EBNA-leader protein (EBNA-LP), 
EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C two EBV-encoded small RNA, 
(EBER-1 and EBER-2) and the non-transcript BART (BamHI-A region rightward 
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transcript) RNAs (Werner et al., 2007). LMP-1 is present in 80-90% of NPC tissues 
and is the principal oncoprotein of NPC (Wang et al., 1985). LMP-1 is an integral 
protein with six transmembrane domains and a carboxy terminus which contains two 
signaling domains known as the C-terminal activating regions 1 and 2 (CTAR 1 and 
2). The CTAR regions directly activate a number of signaling pathways namely the 
nuclear factor κ-B (NF-κB), mitogen-activated protein kinases (MAPK), 
phosphoinositol-3-kinase (PI3K), Janus kinase/signal transducers and activators of 
transcription (JAK/STAT) and the Jun N-terminal kinase (JNK) 
and p38 MAPK (JNK/p38) (Tsao et al., 2002). Activation of these upstream signalling 
pathways by LMP-1 will subsequently activate downstream proteins of several 
pathways. Activation of these proteins will lead to aberrant cell proliferation, cell 
transformation, increase in angiogenesis, metastasis and evasion of apoptosis 
(Tulalamba & Janvilisri, 2012). Roles of the other EBV oncoproteins are extensively 
reviewed in Young and Rickinson, 2004 (Young and Rickinson, 2004). 
 
2.4 Treating Nasopharyngeal Carcinoma – where is the problem? 
Unlike other head and neck cancers, NPC is highly radio- and chemosensitive 
and patients who are diagnosed early respond well to these treatment modalities. The 
5-year survival rate for stage I and stage II patients’ range from 72 to 90% (Chang et 
al., 2004) but unfortunately this is not the case for patients’ who are diagnosed late 
and this is where the problem begins. The 5-year survival rate for stage III and IV 
patients are ~55% and 30%, respectively, mostly attributed to locoregional recurrence 
and metastasis (Chang et al., 2004). Majority of NPC cases are also diagnosed late due 
to trivial clinical symptoms (e.g. headache, nasal and aural obstructions) and patients 
seeking treatment late after the onset of symptoms (Pua et al., 2008). Prognosis for 
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patients suffering from a recurrence or advance disease worsens and therefore they 
respond poorly to the existing treatment modalities (pers. comm. Dr. Shazril Imran 
Shaukat, Clinical Oncologist, IPPT, USM). In light of this, novel or improved 
treatment strategies for NPC are required. Deeper understanding of the molecular 
mechanisms of NPC has led to testing of targeted therapies for NPC management. 
The Epidermal Growth Factor Receptor (EGFR) is expressed in >80% 
advanced NPC patients and hence a promising therapeutic target (Chua et al., 2004). 
A number of EGFR inhibitors namely Cetuximab, Gefitinib and Erlotinib have been 
tested in clinical trials for NPC. In a multi-centre phase II study, recurrent or metastatic 
NPC patients who previously failed platinum-based therapy was tested for 
combination of Cetuximab and Carboplatin. The combination demonstrated median 
overall survival of 7.8 months and was not toxic to patients (Chan et al., 2005). 
Another phase II study which evaluated the combination of Cetuximab with concurrent 
Cisplatin and intensity-modulated radiotherapy (IMRT), in locoregionally advanced 
NPC patients, reported 2-year progression free-survival of 86.5% (Ma et al., 2012). 
Unlike Cetuximab, clinical trials outcome for Gefitinib and Erlotinib were not 
promising. A single centre phase II study assessed the safety and tolerability of 
Gefitinib on 19 recurrent or metastatic NPC patients who failed platinum-based 
treatment. The study concluded that Gefitinib was not toxic but displayed a poor 
response rate (Chua et al., 2008). Similar outcome was obtained when Gefitinib was 
tested on 16 metastatic or locoregionally recurrent NPC patients (Ma et al., 2008). A 
phase II trial evaluated the efficacy of Erlotinib as a second-line treatment for recurrent 
and/or metastatic NPC patients who have undergone treatment with Gemcitabine-
platinum chemotherapy. The outcome was not welcoming as Erlotinib was not 
effective in these patients (You et al., 2012). Collectively, most of these trials were 
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phase II trials, which focused on assessing safety, and tolerability of the EGFR 
inhibitors and only involved a single centre and a small sample size. Larger multi-
centre randomised studies may be needed in the future, to further investigate the 
prospects of the EGFR inhibitors for NPC treatment.  
The Vascular Endothelial Growth Factor (VEGF) is expressed in >60% NPC 
biopsies (Hui et al., 2011a) and was significantly associated with lymph node 
(Wakisaka et al., 1999) and distant metastasis (Guang-Wu et al., 2000). Clinical trials 
with broad spectrum small molecule inhibitors namely Sorafenib and Sunitinib only 
demonstrated a modest clinical effect on NPC patients. Sorafenib is an oral inhibitor 
which inhibits serine/threonine kinases C-Raf and B-Raf and the VEGF receptor 
(VEGFR) -2 and VEGFR-3. Single agent efficacy and safety of Sorafenib was tested 
on recurrent and/or metastatic NPC patients in phase II clinical study. Sorafenib was 
well tolerated by patients but it only demonstrated a modest effect (Elser et al., 2007). 
In another phase II study, patients with a metastatic/recurrent NPC achieved median 
overall survival of 11.8 months after treatment with combination of Sorafenib, 
Cisplatin and 5-Flurouracil (5-FU). Further randomized trials are needed to compare 
the combination tested with combination of Cisplatin and 5-FU (Xue et al., 2013). 
Like Sorafenib, Sunitinib also has broad spectrum activity against many molecules 
such as EGFRs, PDGFRs, c-kit, RET and VEGFR1-3. Preclinical studies showed that 
Sunitinib displayed concentration-dependent growth inhibition of NPC cell lines but 
only weakly enhanced the growth inhibition of Cisplatin and Docetaxel. The drug also 
exhibited significant growth inhibition of NPC xenografts as a single agent but caused 
severe toxicity in mice when it was concurrently administered with Docetaxel (Hui et 
al., 2011c). A phase II study by the same group, reported that Sunitinib displayed a 
modest effect in NPC patients with progressive disease after prior platinum-based 
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chemotherapy. Moreover, development of hemorrhagic complications in patients was 
a concern in this study (Hui et al., 2011b). Bevacuzimab (Avastin®, Genentech, Inc.) 
showed more promising results compared to the other VEGF inhibitors tested for NPC. 
A multicentre phase II clinical study tested the feasibility and safety of combination of 
Bevacuzimab with standard chemoradiation for locoregionally advanced NPC patients. 
Bevacuzimab was well tolerated and addition of this drug to the standard 
chemoradiation delayed the progression of NPC to the distant sites (Lee et al., 2012b). 
The PI3K/AKT/mTOR signaling pathway, which controls key events of cell 
growth, survival and invasion is frequently abrogated in NPC. In recent years, efficacy 
of small molecule inhibitors targeting specific molecules of this pathway have been 
tested for NPC treatment using in vitro and in vivo models. Phosphorylated AKT (p-
AKT) is commonly expressed in NPC tissues and therefore targeting this protein could 
be a promising treatment approach (Loong et al., 2008; Yip et al., 2008; Huang et al., 
2009; Chen et al., 2010). PF-04691502, a potent dual PI3K/mTOR inhibitor, 
demonstrated anti-proliferative activity on NPC cell lines in 2D and 3D cell culture 
models and also displayed anti-tumour activity in the CNE-2 xenograft model. 
Combination of PF-04691502 with Cisplatin or Paclitaxel was not encouraging but 
PF-04691502 showed single agent activity on Cisplatin resistant NPC cell lines (Wong 
et al., 2013). The PIK3CA molecule is another attractive therapeutic target for NPC 
treatment. Amplification of PIK3CA was reported in 40-70% of NPC tissues and hot 
spot mutations of this molecule was reported in low frequencies in NPC cell lines and 
tissues (Hui et al., 2002; Or et al., 2006). BYL719 is a selective inhibitor of PIK3CA. 
The drug showed anti-proliferative activity on NPC cells in 2D and 3D cell culture 
models. Furthermore, the drug demonstrated synergistic effects when combined with 
MEK inhibitor (AZD6244) (MEK is a member of the MAPK signaling pathway – 
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another pathway which is frequently deregulated in NPC) in 3D NPC cell culture 
(Wong et al., 2015). A phase II multi-institutional study investigated the activity of 
AKT inhibitor MK-2206 on 21 recurrent or metastatic NPC patients. The study was 
however terminated as limited clinical activity was observed with this drug (Ma et al., 
2015).  
Recently, a number of immunomodulatory agents exhibited favourable 
response in clinical trials, especially the anti-PD-1 (programmed death 1) and anti-PD-
L1 (programmed death ligand 1) antibodies (Robert et al., 2011; Brahmer et al., 2012). 
The PD-1 receptor inhibitor Keytruda (pembrolizumab, Merck) was approved by the 
Food and Drug Administration (FDA), in September 2014, for the treatment of 
melanoma and has shown impressive results for the treatment of other cancers as well 
(Guha, 2014). The PD-L1 inhibitors are still in clinical development. The PD-1 
receptor is expressed in T and B cells whereas its ligand PD-L1 is expressed in many 
cells in the body including cancer cells. Interaction between the receptor and its ligand 
weakens the immune system (He et al., 2015). Although the PD-1/PD-L1 inhibitors 
are vigorously tested in many cancers their efficacy in NPC are underexplored. In NPC, 
up-regulation of PD-L1 is associated with EBV associated LMP-1 and IFN-γ pathways 
(Fang et al., 2014). Immunohistochemistry staining was conducted to detect 
expression of PD-L1 in 139 NPC patient samples. Findings revealed that patients with 
high expression of PD-L1 have a poorer disease-free-survival (DFS) compared to 
patients with low expression of PD-L1 (median DFS 39.6 months’ vs 65.2 months’). 
Hence, targeting patients with high expression of PD-L1 with PD-1/PD-L1 antibodies 
may be a promising approach for NPC treatment (Fang et al., 2014). 
A goal of this work is to target the BCL-2 family proteins, the critical regulators 
of the intrinsic apoptosis pathway (Delbridge et al., 2016). Some members of this 
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family (e.g. BCL-2, BCL-XL and MCL-1) are deregulated in cancer, making them as 
ideal targets for therapy. The interest to target these molecules for therapy elevated 
with the development of BH3 mimetics such as ABT-737 and ABT-263 (Navitoclax, 
AbbVie), which specifically inhibit these proteins. Efforts to target the anti-apoptotic 
proteins for NPC treatment have been discouraging thus far and therefore sparked our 
interest to investigate the effect of the BH3 mimetics on NPC cells. These points will 
be further elaborated in the following sections, which will first introduce to the 
apoptosis pathways, the BCL-2 family proteins and lastly approaches to target these 
proteins for NPC therapy. 
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2.5 Apoptosis Pathways 
Apoptosis is a form of programmed cell death for neat disposal of aged, 
damaged or diseased cells (Kerr et al., 1972). Apoptosis plays a major role in normal 
developmental processes, including eliminating cells during tissue morphogenesis and 
in the elimination of inactive and self-activating cells during lymphopoiesis (Joaquin 
and Gollapudi, 2001). It is also essential for sustaining normal homeostasis for cell 
populations and abrogation of apoptosis pathways can lead to manifestation of cancer 
or degenerative disease (Tait and Green, 2010). Cells activate apoptosis following 
diverse stress signals namely activation of oncogenes, ultraviolet radiation, growth-
factor deprivation and DNA damage caused by chemotherapeutic agents (Mohana-
Kumaran et al., 2014). Apoptosis can be initiated through the intrinsic (also known as 
the mitochondrial) pathway or the extrinsic (also known as death receptor) pathway.  
 
 
Figure 2.5: The Apoptosis Pathways. The intrinsic apoptosis pathway can be 
activated by various stress signals. For example, DNA damage (stress signal) caused 
by chemotherapeutic agents is sensed by p53. P53 translocate to the nucleus and 
induces genes of pro-apoptotic proteins NOXA and PUMA. Pro-apoptotic proteins in 
turn neutralise the anti-apoptotic proteins. The anti-apoptotic proteins inhibit the 
activation of apoptosis by either binding to the BH3-only proteins or activated BAX 
and BAK. Neutralization of the anti-apoptotic proteins by the BH3-only proteins leads 
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to oligomerisation of effector pro-apoptotic proteins BAX and BAK. BAX and BAK 
induces Mitochondrial Outer Membrane Permeabilization (MOMP) which in turn 
releases cytochrome c into the cytoplasm. Cytochrome c together with APAF-1 form 
the apoptosome and activate caspase-9. Caspase-9 in turn activates the executioner 
caspases -3, -6 and -7 which leads to initiation of apoptosis in the cells. The extrinsic 
apoptosis pathway is activated by the death ligands and their respective death receptors. 
This leads to recruitment of FADD (FAS-associated death domain protein) and 
caspases-8 and -10. Activated caspases-8 and -10 activate the executioner caspases -3, 
-6 and -7 which leads to activation of apoptosis. The intrinsic and the extrinsic pathway 
crosstalk through the actions of caspase-8. Caspase-8 activates BH3-only protein BID 
to truncated BID (tBID). Truncated BID directly activates BAX and BAK and 
thereafter the steps leading to activation of apoptosis follows the intrinsic apoptosis 
pathway. Solid lines: direct inhibition or activation, red boxes: BH3-only pro-
apoptotic proteins, purple boxes: anti-apoptotic proteins and skull: activation of 
apoptosis in the cells. 
 
 
2.6 The Extrinsic Apoptosis Pathway 
The extrinsic apoptosis pathway will only be briefly introduced, as it is not the 
focus of this study. The extrinsic pathway is activated when ligands namely FASL, 
TNF and TRAIL activate their respective death receptors (DR). The DRs are situated 
at the plasma membrane and the members include the tumour necrosis factor (TNF) – 
related apoptosis-inducing ligand (TRAIL) receptor 1 (TRAILR1, also known as DR4 
and TNFRSF10A), TRAIL2 (also known as DR5 and TNFRSF10B), FAS (also known 
as CD95 and APO1) and TNF receptor I (TNFR1, also known as TNFRSF1A) (Ichim 
and Tait, 2016). These death receptors contain a cytosolic “death domain” and through 
this death domain, they interact with the other cytosolic proteins. Once the ligands 
bind to the death receptors, the receptors recruit the cytosolic FADD (FAS-associated 
death domain protein) and caspases-8 and -10 (Figure 2.5). Activation of caspase-8 
leads to activation of the executioner caspases such as caspases-3 and -7. The 
executioner caspases then initiate the proteolytic mechanics of apoptosis in cells 
(Ichim and Tait, 2016) (Figure 2.5). It is important for our purpose that the extrinsic 
pathway can initiate the intrinsic apoptosis pathway. The crosstalk between the two 
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pathways is performed through the actions of caspase 8. Caspase 8 truncates and 
activates BH3-only protein BID of the intrinsic apoptosis pathway to truncated form 
BID (tBID) (Li et al., 1998; Luo et al., 1998) (Figure 2.5). Thereafter the pathway 
leading to activation of apoptosis follows the intrinsic pathway (see the next section). 
 
2.7 The Intrinsic Apoptosis Pathway 
The intrinsic pathway can be activated following diverse stress signals such as 
hypoxia, nutrient deprivation and DNA damage which is caused by chemotherapeutic 
agents (Mohana-Kumaran et al., 2014). For example, cell senses DNA damage due to 
treatment with chemotherapeutic agents via the p53 tumour suppressor protein 
(Junttila and Evan, 2009). Once the stress is sensed, p53 is stabilised and accumulated 
in the cell. Next, p53 translocate to the nucleus and induces the expression of genes, 
which are involved in the intrinsic pathway namely pro-apoptotic proteins NOXA and 
PUMA (Mohana-Kumaran et al., 2014) (Figure 2.5). Activation of these proteins 
neutralise the anti-apoptotic proteins. Inactivation of the anti-apoptotic proteins leads 
to translocation of BAX from the cytoplasm to the outer mitochondrial membrane 
(OMM). At the OMM, BAX oligomerises with BAK to induce mitochondrial outer 
membrane permeabilisation (MOMP) leading to release of mitochondrial cytochrome 
c (Mohana-Kumaran et al., 2014) (Figure 2.5). Cytochrome c interacts with the 
monomeric cytosolic protein APAF-1 (apoptotic-protease-activating factor-1), 
initiating the formation of apoptosome, which activates initiator caspase-9 (Figure 2.5). 
Activated caspase-9 activates caspases-3, 6 and -7, which in turn activate apoptosis 
(Ichim and Tait, 2016) (Figure 2.5). 
 
 
